Skip to main content
Signal8
Launch Terminal
Cockroft Bettina M. profile photo

Bettina M. Cockroft

CIK: 0001900452

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

Annexon, Inc. logo
ANNX

Annexon, Inc.

Director
CNS Pharmaceuticals, Inc. logo
CNSP

CNS Pharmaceuticals, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (3 total)

  • Annexon, Inc. logo
    ANNX

    Annexon, Inc.

    Jun 11, 2026
    Award(A)

    Stock Option (Right to Buy)

    Direct
    65K shares-
  • CNS Pharmaceuticals, Inc. logo
    CNSP

    CNS Pharmaceuticals, Inc.

    Nov 17, 2025
    Award(A)

    Option to purchase common stock

    Direct
    1.5K shares-
  • Annexon, Inc. logo
    ANNX

    Annexon, Inc.

    Jun 5, 2025
    Award(A)

    Stock Option (Right to Buy)

    Direct
    55K shares-

1-3 of 3

About Cockroft Bettina M.

Cockroft Bettina M. (SEC CIK 0001900452) files insider reports with the SEC as Director of Annexon, Inc. (ANNX) and Director of CNS Pharmaceuticals, Inc. (CNSP).

Signal8 holds 3 ownership filings by Cockroft Bettina M., all Form 4s, filed between Jun 9, 2025 and Jun 15, 2026. Those filings report 3 transactions, from Jun 5, 2025 to Jun 11, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Cockroft Bettina M.'s filings is in BRISBANE, CA.

Recent filings by Cockroft Bettina M.

  • Jun 11, 2026: Grant or award of ANNX derivative securities (Form 4, code A).
  • Nov 17, 2025: Grant or award of CNSP derivative securities (Form 4, code A).
  • Jun 5, 2025: Grant or award of ANNX derivative securities (Form 4, code A).

Other insiders filing for Annexon, Inc. (ANNX)

How to read Form 4 transaction codes